319 related articles for article (PubMed ID: 21813027)
1. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.
Kang JH; Song KH; Jeong KC; Kim S; Choi C; Lee CH; Oh SH
BMC Cancer; 2011 Aug; 11():334. PubMed ID: 21813027
[TBL] [Abstract][Full Text] [Related]
2. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
3. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
Chun J; Kim YS
Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
Mei Y; Liao X; Zhu L; Yang H
J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
[TBL] [Abstract][Full Text] [Related]
5. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
[TBL] [Abstract][Full Text] [Related]
6. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
Simeone AM; Nieves-Alicea R; McMurtry VC; Colella S; Krahe R; Tari AM
Int J Oncol; 2007 Apr; 30(4):785-92. PubMed ID: 17332916
[TBL] [Abstract][Full Text] [Related]
8. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Chang XZ; Li DQ; Hou YF; Wu J; Lu JS; Di GH; Jin W; Ou ZL; Shen ZZ; Shao ZM
Breast Cancer Res; 2007; 9(6):R76. PubMed ID: 17980029
[TBL] [Abstract][Full Text] [Related]
9. AGPAT9 suppresses cell growth, invasion and metastasis by counteracting acidic tumor microenvironment through KLF4/LASS2/V-ATPase signaling pathway in breast cancer.
Fan SH; Wang YY; Wu ZY; Zhang ZF; Lu J; Li MQ; Shan Q; Wu DM; Sun CH; Hu B; Zheng YL
Oncotarget; 2015 Jul; 6(21):18406-17. PubMed ID: 26110566
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
11. The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7.
Fang XJ; Jiang H; Zhao XP; Jiang WM
BMC Cancer; 2011 Jul; 11():290. PubMed ID: 21749678
[TBL] [Abstract][Full Text] [Related]
12. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
[TBL] [Abstract][Full Text] [Related]
13. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response.
Zhong Y; Zhang F; Sun Z; Zhou W; Li ZY; You QD; Guo QL; Hu R
Mol Carcinog; 2013 Oct; 52(10):824-34. PubMed ID: 22593043
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model.
Li D; Qin Q; Wang XY; Shi HS; Luo M; Guo FC; Wang W; Wang YS
Oncol Rep; 2014 Mar; 31(3):1287-95. PubMed ID: 24378474
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Han C; Michalopoulos GK; Wu T
J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
[TBL] [Abstract][Full Text] [Related]
17. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.
Huang Q; Wu YY; Xing SJ; Yu ZW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
Chen J; Wang W; Wang H; Liu X; Guo X
Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway.
Mao L; Yuan L; Slakey LM; Jones FE; Burow ME; Hill SM
Breast Cancer Res; 2010; 12(6):R107. PubMed ID: 21167057
[TBL] [Abstract][Full Text] [Related]
20. c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2.
Li X; Liu X; Xu W; Zhou P; Gao P; Jiang S; Lobie PE; Zhu T
J Biol Chem; 2013 Jun; 288(25):18121-33. PubMed ID: 23649631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
